Seeking Alpha

GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming...

GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming the company improperly delayed the market entry of competitive generic alternatives to its nasal spray Flonase. The settlement was reached with AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK), among others, who maintained that GSK had abused the citizen's petition process to monopolize the market and overcharge for the spray by restricting access to less expensive generic versions.
From other sites
Comments (1)
  • TwistTie
    , contributor
    Comments (2476) | Send Message
     
    Bears: 2, Bulls: 0

     

    And I just started following this one.
    19 Dec 2012, 04:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs